Navigation Links
Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease
Date:10/14/2008

NEW YORK, Oct. 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research awarded a total of $2 million to five research teams to speed development of effective therapies for the under-addressed cognitive and mood-related symptoms of Parkinson's disease. Patients often report these symptoms, which range from problems with executive function (the ability to formulate, sequence, and execute plans) to dementia; depression, apathy and anxiety; and behavioral issues including problems with impulse control, to be among the most difficult aspects of living with PD.

The funding will support pre-clinical and clinical research projects under the Foundation's Cognitive Deficits and Mood Disorders in Parkinson's Disease initiative, made possible by generous leadership funding from Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

"Clinicians and patients alike report how disabling the cognitive and mood effects of PD can be, yet these symptoms are systematically under-researched and are poorly understood," said Katie Hood, CEO of The Michael J. Fox Foundation. "We are thrilled to have found a like-minded partner in Merck Serono so that we can push this work forward."

Elmar Schnee, President of Merck Serono, said: "Merck Serono recognizes the critical need for new therapies to alleviate PD-related cognitive dysfunction. We are pleased to stand side by side with The Michael J. Fox Foundation in prioritizing and supporting research with potential to help speed development of effective treatments that will allow every patient to live a fuller and more satisfying life."

The development of treatments for cognitive and mood symptoms of Parkinson's has been hindered by a lack of preclinical models to explain these features of the disease; a lack of basic knowledge of the mechanisms that underlie these symptoms; inadequate understanding of the clinical features of these symptoms in PD; and a need for relevant clinica
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
2. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
3. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
4. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
7. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
8. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
9. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
10. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
11. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... REDWOOD CITY, Calif., March 19, 2012 Ingenuity Systems, ... life science researchers, today announced that the Weill Cornell ... iReport for use in its sequencing core facility.  Variant ... the output of whole genome and exome sequencing experiments ...
... 19, 2012  Johnson & Johnson (NYSE: JNJ) will provide ... parties on Monday, March 26th at approximately 10:30 ... College of Cardiology (ACC) Annual Scientific Sessions in ... of the EINSTEIN-PE study in treating patients with ...
Cached Medicine Technology:Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... of awards in the 2007 Association TRENDS All-Media Contest, ... Society Magazine as well as the category won by ... honored at the Salute to Association Excellence event on ... the official publication of the Society for Biomolecular Sciences. ...
... the past two decades and is now second to back ... than men to suffer from persistent neck pain, in particular ... a computer keyboard. Previous studies have shown conflicting results as ... but there has not been enough high-quality research in this ...
... are looking for,that magic pill that will make us look and ... longer a pill, and nutrition trends of 2008 will,put you on ... all,the hype," said Dr. Clive R. Spray, a biochemist and leader ... can we improve the health of our family and ourselves?, ...
... are so many health,recommendations in the media these days that ... they can make for better,health in the year ahead. ISSA ... strong -- for their top,recommendations for the 10 best things ... ahead. Here are the results of that survey:, ...
... MCKINNEY, Texas, Jan. 4 Torchmark Corporation,(NYSE: ... two of its leading,insurance subsidiaries, United American Life ... from Delaware to Nebraska. Torchmark,plans to redomesticate other ... the premium tax rates in a number of ...
... DaVita Inc. (NYSE:,DVA) announced today that it and ... partnership to provide dialysis and vascular,access services, as ... the greater Phoenix area. The partnership will own ... to provide patients with,access to all available treatment ...
Cached Medicine News:Health News:Strength training of neck muscles relieves chronic pain 2Health News:Nutrition Trends of 2008 2Health News:Nutrition Trends of 2008 3Health News:Nutrition Trends of 2008 4Health News:International Sports Sciences Association's Ten Best Resolutions for Better Health in 2008 2
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: